Patient Stories

Matt Singer

matt-singer-patientMatt, never let hemophilia stand in his way. As a child, he wore a helmet and knee pads to protect him while playing, but he said, "I had a lot of friends from an early age that just accepted it." When, he needed to use a wheelchair due to bleeds in his ankles, his classmates eagerly volunteered to push him around. Matt's parents were tireless in their efforts to explain hemophilia in kid's terms. Although, hemophilia is most often a genetic disease, but in Matt’s case there was no family history and his condition was deemed a random mutation. His parents vowed from infancy to make his life as normal as possible. Matt has needed Factor VIII infusions his entire life, from several times a week which he has administered himself since childhood.

In high school, Matt volunteered with the ambulance squad, became CPR certified and today works as a registered nurse in emergency and trauma. He believes that having hemophilia has helped him empathize with children who have chronic medical illnesses and serves as a positive role model. Matt worked as a counselor at Paul Newman's Hole in the Wall Camp for children with chronic illnesses that he attended as a child and volunteers for the Delaware Valley Chapter of the National Hemophilia Foundation.

Judy Tretsven-Parker

patient-judyJudy lives with severe alpha-1 antitrypsin deficiency (A1AD), a genetic condition that affects the lungs and makes it difficult to breath. Often referred to as genetic emphysema, this inherited condition is more deadly than the type caused by smoking. Air and pollutants eat away at a patient's lungs and may result in death by mid-40's. I was diagnosed at age 28 after chronic colds, bronchitis and lung infections that did not respond to antibiotics. I was given 10 years to live. I started alpha-1 proteinase inhibitor treatments in 1989. I beat the odds and celebrated my 50th birthday because of four things: A1P1 treatments, my doctors, a positive attitude and exercise. I am extremely grateful that I never needed a major lung surgery, or any lung-related surgery. In 2005, I had a port-a-cath implanted so I can self-infuse. With replacement therapy, my health has stabilized and the deterioration of my lungs is expected to follow normal aging patterns. I also receive early treatment for a cold and avoid tobacco smoke, noxious fumes, dust and pollution. I work to inform others about the symptoms and treatment of A1AD. In 2006, I became an A1AD support group leader of the "Wisconsin Alpha Pack," covering the Northern Lights Region (Northern Wisconsin). Our mission is to offer support to those in the Wisconsin area affected by A1AD bring about awareness in the local community.

Stuart Butler

patient-stewartA playground accident led to 5 year-old Stuart Butler's diagnosis of Guillain-Barre Syndrome (GBS). What initially appeared to be a bump and a bruise quickly escalated to no responsive reflexes. A spinal tap confirmed elevated protein levels, a risk of respiratory failure and that GBS was accelerating throughout Stuart's body.

A series of four gamma globulin treatments (IVIG) began at 24-hour intervals. Eight days later, he left the hospital in a wheelchair with a walker. He required physical and occupational therapy five days a week. Within 10 days, progress was slipping and we contacted the family and child support group of the GBS Foundation. Further tests revealed that his nerve axons showed damage. Stuart faced more therapy and missed six months of school but he worked hard and by age six could walk, ride a bike and attend day camp. He maintained a sense of humor, learned about people with conditions worse than his own, began to understand empathy and believed in himself. We are so proud. Although our experience was life-changing, we feel so thankful. Our love and faith have grown and we celebrate each new day.

Jamie van den Berg

patient-jamieI am 25 years old and live in the Netherlands. My girlfriend Sabrina and I are very happy and recently moved in together. I have von Willebrand Disease, an inherited bleeding disorder, and recently went to my first meeting of the von Willebrand patient group of the Netherlands Hemophilia Society, the NVHP.

During the meeting, I was asked what type of von Willebrand I am suffering from and I could not really answer that question. I know I have von Willebrand and have been able to handle that quite well. I do not see it as an obstacle and would not want to call it that. The only thing I find frustrating is that my parents did not allow me to join the soccer club when I was young. I am sure I would have made the Dutch national team by now. Soccer was not going to work, so I had to choose a different sport, which was swimming. I did that for a number of years, after which I felt a need for a challenge and started canoeing first on calm waters, and then in the ocean. By the time I was 15 years old, I was a wild water canoe instructor in Slovenia.

Looking back, my parents should have just let me play soccer, since that would have been conveniently close to the Academic Hospital in Leiden. Instead, I was 15 and in Slovenia, without my parents. Despite not having been able to start my soccer career, I have done everything I wanted and have not allowed von Willebrand to stand in my way. I have conquered the wildest rivers, climbed the highest mountains in Europe, traveled through Australia by myself for three months, and enjoyed snowboarding, despite getting stuck on a mountain for a night. To me, von Willebrand Disease has become part of me, or better, has always been part of me.

Source: World Federation of Hemophilia

Overview

Plasma protein therapies (PPTs) treat a variety of medical conditions. Many of these are rare, chronic and often genetic conditions that are life threatening.

PPTs replace missing or deficient proteins which are obtained from human plasma. Patients generally require regular infusions or injections of these therapies for the duration of their lives.

PPTs are considered sole-source biologic products because no generic or chemical substitutions exist.

Read more: Overview

Plasma Protein Therapies

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed aliquam, lorem et sollicitudin tincidunt, arcu erat placerat mi, at gravida nisi massa id quam. Etiam bibendum, neque sollicitudin dignissim lacinia, leo mauris condimentum mi, eget varius ante leo et libero. Etiam mollis, mi id cursus tempor, leo nisl volutpat tortor, id sollicitudin neque nibh ut nunc. Sed augue enim, consequat et sagittis ut, gravida vitae enim. Praesent urna nisl, lacinia pulvinar convallis sollicitudin, cursus non urna. Integer porttitor commodo elit, nec vehicula nisl accumsan convallis. Nam et felis justo, a aliquam odio. Pellentesque egestas scelerisque odio, eu pulvinar lectus euismod quis. Donec auctor elit at odio pharetra laoreet. Morbi ac risus ut tellus congue interdum. Aenean ut ipsum at nisi tempus cursus. Pellentesque convallis condimentum orci non mollis. Donec ut urna ut neque sodales scelerisque quis at arcu. Curabitur hendrerit ullamcorper nibh vel scelerisque. In consequat sagittis mi, id consequat dui aliquet eget.

Read more: Plasma Protein Therapies

Who Needs Plasma Therapies?

Rare Diseases and Conditions

Plasma-derived therapies replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. The patients that rely on these therapies generally require regular infusions or injections throughout their lives.

The diseases and conditions treated by plasma protein therapies are considered rare diseases because they affect a relatively small percent of the population; most are genetic, chronic conditions.


Alpha-1 Proteinase Inhibitor therapies are used to treat:

Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency is one of the most common serious hereditary disorders in the world and can result in life-threatening liver disease in children and adults and lung disease in adults. It is often referred to as genetic emphysema.


C1 Esterase Inhibitor therapies are used to treat:

Hereditary Angioedema

Hereditary Angioedema is caused by a missing C1 esterase inhibitor protein (C1-INH), which helps regulate inflammation. Patients can experience edema (severe swelling) which can be fatal if the airway becomes obstructed.


Coagulation Factors are used to treat:

Hemophilia A

Hemophilia A is a heredity bleeding disorder that is caused by a lack of clotting factor VIII. As a result, individuals with this condition suffer from bleeding into joints and other complications. For the most part, men have hemophilia A as the defective gene is found on the X chromosome. A woman who has the defective gene is considered a carrier and any male offspring have a 50% chance of having hemophilia A and female offspring a 50% chance of being a carrier. It affects one in 10,000 people. With treatment, individuals are able to lead relatively normal lives.

Hemophilia B

Hemophilia B is a blood clotting disorder caused by a mutation of the Factor IX gene. It is rarer than hemophilia A and affected royal families in both Europe and Russia. It affects one in 25,000 men. Replacement of Factor IX through recombinant therapy allows individuals to lead relatively normal lives.

Von Willebrand Disease

The most common bleeding disorder, Von Willebrand affects about 1.25 million men and women worldwide, although it is estimated that as many as 3 million are undiagnosed. Common symptons include excessive menstrual bleeding and nosebleeds. There are several kinds of VWD and symptom severity varies. With proper treatment, individuals may live relatively normal lives.

Antithrombin III Deficiency

Antithrombin III is a protein that prevents blood clots from forming.  It is caused by an abnormal gene that may lead to blood clots.  Data on incidence is uncertain.


Immune Globulins are used to treat:

Primary Immunodeficiency Disease (PID)

PID is a genetic condition that prevents an individual's immune system from functioning properly. The World Health Organization (WHO) estimates that there may be as many as 150 PIDs. PID results a high susceptibility to infection and an inability to fight them with traditional antiobiotics.

Chronic Inflammatory Demyelinating  Polyneuropathy (CIDP)

CIDP is a rate autoimmune disorder that affects the peripheral nervous system of both children and adults. Nerves in the arms and legs may become weakened and lead to paralysis. It is sometimes referred to as Guillain-Barre Syndrome.

Idiopathic Thrombocytpenic Purpura (ITP)

ITP is an autoimmune blood disorder that results in reduced blood platelet levels, essential for blood clotting.

Kawasaki Disease

A condition that primarily affects children under the age of five and is the leading cause of acquired heart disease in children. If it is not detected, it can result in heart damage and death.

In addition to the lifesaving therapies used to treat rare diseases, plasma-derived therapies are also used in everyday medicine and emergency and critical care situations, as well as in preventive medicine. PLASMA PROTEINS ARE ALSO USED TO TREAT:

Read more: Who Needs Plasma Therapies?

Copyright © 2023 PPTA. All rights reserved. Sitemap | Privacy Policy
Realisation by Welldotcom - Puntgaaf Internetbureau